-

Viz.ai Appoints Dr. Andrew M. Ibrahim as Chief Clinical Officer to Advance AI-Powered Healthcare

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the appointment of Andrew M. Ibrahim, MD, MSc as its new Chief Clinical Officer (CCO). Dr. Ibrahim will lead Viz.ai’s clinical strategy and oversee the integration of generative artificial intelligence into healthcare delivery to improve quality, efficiency, and patient outcomes. He will report to Chris Mansi, MD, CEO and co-founder of Viz.ai.

Dr. Ibrahim is a board-certified general surgeon and internationally recognized expert in healthcare delivery. He has authored more than 200 scientific publications and served as principal investigator on research funded by the National Institutes of Health and the Agency for Healthcare Research and Quality. His work has appeared in leading journals including JAMA, Health Affairs, and NEJM Catalyst, and he has delivered invited lectures across five continents. Furthermore, he has been invited to testify in Congress on AI regulation and reimbursement this month.

“Andrew brings an unparalleled combination of clinical expertise, research leadership, and healthcare innovation experience,” said Chris Mansi, CEO and co-founder of Viz.ai. “Our platform has evolved dramatically over the past few years, now screening millions of patients’ multimodal data to ensure the right patient reaches the right specialist at the right time across cardiology, neurology, oncology, helping doctors streamline their workflow and reduce variations in care. Andrew’s leadership will ensure our solutions continue to deliver meaningful impact to patients, providers, and health systems at scale.”

Dr. Ibrahim is the George D. Zuidema Professor at the University of Michigan, where he practices as a general surgeon and conducts research at the intersection of surgery, healthcare delivery, and innovation. He is also the pioneer of the widely adopted “Visual Abstract,” an innovation in scientific communication now implemented by more than 100 medical journals worldwide. Prior to joining Viz.ai, Dr. Ibrahim served as Chief Medical Officer and Senior Principal at HOK, a global design and architecture firm, where he led master planning and design projects spanning more than two million square feet and totaling over four billion dollars across healthcare, life sciences, aviation, and workplace sectors. Dr. Ibrahim earned his medical degree from Case Western Reserve University and completed his general surgery training and a master’s degree in Healthcare Delivery at the University of Michigan.

“I am thrilled to join Viz.ai at such a pivotal moment in healthcare,” said Dr. Ibrahim. “AI is transforming how we identify patients earlier, activate care teams faster, and improve outcomes at scale. I look forward to working with the Viz.ai team to ensure our clinical strategy delivers even greater impact for patients, providers, and health systems worldwide.”

About Viz.ai

Viz.ai uses AI algorithms and machine learning to accelerate diagnosis and care across 1,800 hospitals and health systems in the U.S. and Europe. Viz.ai One® is an AI-powered care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai delivers significant value to patients, providers and life sciences companies. In 2025, Viz.ai was ranked the #1 Healthcare AI Platform by hospitals and health systems in the Black Book Research survey. For more information visit Viz.ai.

Contacts

Media Contact
Carolyn Jones
carolyn.jones@viz.ai

Daniel Yunger
daniel.yunger@kekstcnc.com

Viz.ai


Release Versions

Contacts

Media Contact
Carolyn Jones
carolyn.jones@viz.ai

Daniel Yunger
daniel.yunger@kekstcnc.com

Social Media Profiles
More News From Viz.ai

New Data Show Viz.ai’s AI-Enabled ECG Screening Increases Detection and Accelerates Diagnosis of Hypertrophic Cardiomyopathy

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data demonstrating how Viz HCM enables faster, accurate detection of hypertrophic cardiomyopathy (HCM), to help ensure that more patients are identified. Two studies, which will be presented at the American Heart Association (AHA) Scientific Sessions 2025, show Viz.ai’s real-world ability to identify more patients with HCM years earlier than current...

Viz.ai Launches Viz Assist: The First Multimodal AI Agent Platform for Faster Treatment and Better Outcomes

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz Assist™, a suite of autonomous AI agents that significantly enhance how care teams identify, prioritize, and act on critical patient data.1 Viz Assist marks a major step forward in Viz.ai’s mission to use technology to reduce time to treatment and improve patient outcomes. Viz Assist incorporates inputs from ambient listening and the electronic...

Viz.ai Launches Viz ACS™ to Accelerate Treatment for Heart Attack and Reduce Unnecessary Activations

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz ACS, a new solution in the Viz Cardio™ Suite. Designed to unite the acute coronary syndrome (ACS) care team on a single platform, Viz ACS provides Emergency Department (ED) physicians and cardiologists with the same high-quality ECGs and patient data in real time. This streamlined workflow can help improve communication, speeds treatment, and re...
Back to Newsroom